Trial intelligence / Profile preview

Pyrotinib tolerability optimization in HER2-positive early breast cancer

ChiCTR2200060339Phase 2Not yet recruiting

Sponsor

First Affiliated Hospital of Chongqing Medical University

Start

May 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1